- Home
- FTHM vs PULM Comparison
FTHM vs PULM Comparison
Compare FTHM & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTHM
- PULM
- Stock Information
- Founded
- FTHM 2010
- PULM 2003
- Country
- FTHM United States
- PULM United States
- Employees
- FTHM N/A
- PULM N/A
- Industry
- FTHM Real Estate
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- FTHM Finance
- PULM Health Care
- Exchange
- FTHM Nasdaq
- PULM Nasdaq
- Market Cap
- FTHM 33.6M
- PULM 33.2M
- IPO Year
- FTHM 2020
- PULM N/A
- Fundamental
- Price
- FTHM $1.27
- PULM $6.38
- Analyst Decision
- FTHM Buy
- PULM
- Analyst Count
- FTHM 1
- PULM 0
- Target Price
- FTHM $2.50
- PULM N/A
- AVG Volume (30 Days)
- FTHM 87.1K
- PULM 60.0K
- Earning Date
- FTHM 08-11-2025
- PULM 08-12-2025
- Dividend Yield
- FTHM N/A
- PULM N/A
- EPS Growth
- FTHM N/A
- PULM N/A
- EPS
- FTHM N/A
- PULM N/A
- Revenue
- FTHM $357,816,000.00
- PULM $1,921,000.00
- Revenue This Year
- FTHM $32.40
- PULM N/A
- Revenue Next Year
- FTHM $18.04
- PULM $134.88
- P/E Ratio
- FTHM N/A
- PULM N/A
- Revenue Growth
- FTHM 5.80
- PULM N/A
- 52 Week Low
- FTHM $0.65
- PULM $1.78
- 52 Week High
- FTHM $3.37
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- FTHM 53.30
- PULM 39.53
- Support Level
- FTHM $1.27
- PULM $6.26
- Resistance Level
- FTHM $1.39
- PULM $6.96
- Average True Range (ATR)
- FTHM 0.10
- PULM 0.85
- MACD
- FTHM 0.01
- PULM -0.11
- Stochastic Oscillator
- FTHM 61.54
- PULM 39.71
About FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).